Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Amgen logo

Amgen

Status

Completed

Conditions

Juvenile Rheumatoid Arthritis

Treatments

Drug: Enbrel®

Study type

Observational

Funder types

Industry

Identifiers

NCT00078793
016.0026
20021626

Details and patient eligibility

About

This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or without other DMARDs.

Enrollment

600 patients

Sex

All

Ages

2 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

  • JRA by American College of Rheumatology (ACR) criteria - Active joints - Initiate etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone, or methotrexate with other DMARDs within 6 months of entry into Registry
  • Polyarticular or systemic RA in 3 or more joints at start of treatment

Trial design

600 participants in 1 patient group

Methotrexate group
Description:
Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
Treatment:
Drug: Enbrel®

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems